Flatexdegiro plans to merge with Flatexdegiro Bank in 2026

Flatexdegiro plans to merge with Flatexdegiro Bank in 2026

Phibro Animal Health Corporation reported robust financial results for the fourth quarter of 2025, with a 39% increase in revenue to $378.7 million and a 49% rise in adjusted EBITDA to $60.6 million. The company's Animal Health segment saw a 53% year-over-year increase in net sales to $292.5 million, driven by a 77% jump in MFA and other portfolio sales, bolstered by the integration of Zoetis' medicated feed additive portfolio.

The integration of Zoetis' MFA business contributed $94.5 million in sales in Q4, with full independence expected by the end of 2025. The company's strategic initiatives, including the Fibro Forward program, are expected to peak in FY2027 and contribute significantly to earnings growth.

Phibro's guidance for FY2026 includes net sales of $1.425 billion to $1.475 billion, representing a 10% to 14% year-over-year increase, and adjusted EBITDA of $225 million to $235 million, a 22% to 28% increase. The company's adjusted EPS is expected to range from $2.52 to $2.70, with adjusted net income projected to be between $103 million and $110 million.

The earnings call highlighted differing views on the performance and future growth of the MFA business, the impact of tariffs, and the integration timeline of the Zoetis acquisition. However, management expressed confidence in the underlying demand and the company's ability to manage tariffs through inventory management, supplier renegotiation, and pricing adjustments.

References:
[1] https://www.ainvest.com/news/phibro-q4-2025-earnings-call-contradictions-mfa-growth-zoetis-integration-tariff-impact-inventory-strategy-revealed-2508/